Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Randomized Study of MTX-001 Injections for Non-Healing Venous Stasis Ulcers with Standard Wound Care
Researchers are evaluating the safety and effectiveness of MTX-001 in treating non-healing venous stasis ulcers VSU that have not improved after at least 4 weeks of standard wound care. This randomized, double-blind, placebo-controlled study includes patients with specific ulcer characteristics and aims to better understand MTX-001s potential benefits in wound healing compared to placebo. The study has two parts an initial lead-in phase where patients received MTX-001 weekly or every two weeks alongside standard care, followed by a randomized phase where about 70 patients receive either MTX-001 or a placebo injection weekly along with standard wound care. Treatments involve subcutaneous injections into or around the ulcer during weekly clinic visits over 12 weeks. Participants undergo safety and efficacy assessments at screening, baseline, and weeks 4, 8, and 12, including measuring wound surface area, pain levels, and overall wound healing progress. Researchers track changes in ulcer size, pain, quality of life, and total wound closure. The study also monitors tolerability and safety throughout the 12-week treatment period.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.